JP Morgan Chase’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

JP Morgan Chase’s Portfolio VINC Stock Details VINC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1	Closed	-$1	–	7878
2025 Q1	$1	Hold	1	–	–	﹤0.01%	7275
2024 Q4	$6	Sell	1 -2	-67%	-$13	﹤0.01%	7331
2024 Q3	$42	Buy	+3	New	+$41	﹤0.01%	7152
2023 Q3	–	Sell	-20	Closed	-$512	–	7785
2023 Q2	$512	Buy	+20	New	+$572	﹤0.01%	6546
2022 Q2	–	Sell	-385	Closed	-$31K	–	6976
2022 Q1	$31K	Buy	385 +72	+23%	+$8.89K	﹤0.01%	5959
2021 Q4	$64K	Sell	313 -83	-21%	-$20.7K	﹤0.01%	5856
2021 Q3	$128K	Buy	396 +44	+13%	+$12.8K	﹤0.01%	5446
2021 Q2	$91K	Buy	+352	New	+$107K	﹤0.01%	5575

Other funds holding VINC

BTC

Bank & Trust Company Litchfield, Illinois $158M AUM 35.48% 1-Year Est. Return

JP Morgan Chase's VINC Position: Q2 2025 in Review

JP Morgan Chase sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q2 2025, closing a stake of 1 share — an estimated $1 sold.

JP Morgan Chase first reported a position in VINC in Q2 2021 and held it in 8 quarters. The position peaked at $128K in Q3 2021. 1 fund tracked by Wall St. Rank holds VINC as of Q2 2025.

JP Morgan Chase reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q2 2025 after selling out during the quarter.
JP Morgan Chase sold 1 Vincerx Pharma, Inc. Common Stock share in Q2 2025, an estimated $1.
JP Morgan Chase first reported a position in Vincerx Pharma, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
JP Morgan Chase's Vincerx Pharma, Inc. Common Stock position peaked at $128K in Q3 2021.
1 fund tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q2 2025.

Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.